Oxford BioDynamics Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Oxford BioDynamics şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-161.5%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-161.5%
Gelecekteki Temettü Verimi	n/a
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

Here's Why We're Watching Oxford BioDynamics' (LON:OBD) Cash Burn Situation

Jan 18

Here's Why We're A Bit Worried About Oxford BioDynamics' (LON:OBD) Cash Burn Situation

Oct 08

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: OBD şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: OBD şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Oxford BioDynamics Piyasaya Karşı Temettü Getirisi

OBD temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (OBD)	n/a
Pazarın Alt %25'i (GB)	2.2%
Pazarın En İyi %25'i (GB)	6.0%
Sektör Ortalaması (Life Sciences)	0.7%
Analist tahmini (OBD) (3 yıla kadar)	n/a

Önemli Temettü: OBD şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, OBD şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: OBD şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: OBD herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Oxford BioDynamics Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

Oxford BioDynamics Publishes Study on Prognostic Covid Severity Test and Long COVID Analysis

New major risk - Market cap size

New major risk - Shareholder dilution

New major risk - Share price stability

First half 2024 earnings released: UK£0.023 loss per share (vs UK£0.032 loss in 1H 2023)

New major risk - Financial position

OBD Develops Multi-Cancer Diagnostic Test for Dogs

Oxford BioDynamics Plc to Report First Half, 2024 Results on Jun 18, 2024

Oxford BioDynamics Plc Opens Clinical Testing Facility in the UK to Perform EpiSwitch Prostate Screening (PSE) Blood Test

Oxford BioDynamics Plc has filed a Follow-on Equity Offering in the amount of £9 million.

Oxford BioDynamics Plc, Annual General Meeting, Mar 27, 2024

Here's Why We're Watching Oxford BioDynamics' (LON:OBD) Cash Burn Situation

Full year 2023 earnings released: UK£0.073 loss per share (vs UK£0.067 loss in FY 2022)

Oxford BioDynamics Plc to Report Fiscal Year 2023 Results on Jan 17, 2024

New minor risk - Financial data availability

Non-Executive Director recently sold UK£298k worth of stock

Non-Executive Director recently sold UK£52k worth of stock

Oxford BioDynamics Plc Launches 94% Accurate PSE Test in US and UK

New major risk - Shareholder dilution

First half 2023 earnings released: UK£0.032 loss per share (vs UK£0.031 loss in 1H 2022)

Oxford BioDynamics Plc to Report First Half, 2023 Results on May 30, 2023

Oxford BioDynamics Plc Announces Prostate Screening EpiSwitch® Blood Test Significantly Enhances Overall Detection Accuracy for At Risk Men

Non-Executive Director recently bought UK£51k worth of stock

Full year 2022 earnings released: UK£0.067 loss per share (vs UK£0.072 loss in FY 2021)

Oxford BioDynamics Plc, Annual General Meeting, Mar 30, 2023

Oxford BioDynamics Plc Announces Initial Assessment of EpiSwitch Assay in Amyotrophic Lateral Sclerosis Trial

Less than half of directors are independent

Oxford BioDynamics Plc, Annual General Meeting, Oct 27, 2022

Here's Why We're A Bit Worried About Oxford BioDynamics' (LON:OBD) Cash Burn Situation

Oxford BioDynamics plc Announces US Reimbursement Code for CiRT Now Available

First half 2022 earnings released

Oxford Biodynamics plc Checkpoint Inhibitor Response Test (Episwitch® Cirt) Now Available in the UK

Oxford BioDynamics Plc to Report First Half, 2022 Results on Jun 28, 2022

Oxford BioDynamics Plc Presents Additional Data at ASCO 2022

Less than half of directors are independent

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Oxford BioDynamics Plc Announces Successful Clinical Validation and US Launch of its Checkpoint Inhibitor Response Test

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Oxford BioDynamics Plc Provides Update on EpiSwitch CST and CiRT tests

Is Oxford BioDynamics (LON:OBD) In A Good Position To Invest In Growth?

First half 2021 earnings released: UK£0.033 loss per share (vs UK£0.022 loss in 1H 2020)

Oxford BioDynamics (LON:OBD) Is In A Good Position To Deliver On Growth Plans

Oxford BioDynamics Plc Publishes Results of Biomarker Discovery Program Being Used for Development of Its EpiSwitch Covid-19 Severity Test

Full year 2020 earnings released: UK£0.047 loss per share (vs UK£0.03 loss in FY 2019)

Full year 2020 earnings released: UK£0.047 loss per share (vs UK£0.03 loss in FY 2019)

Oxford BioDynamics Plc, Annual General Meeting, Mar 24, 2021

Oxford BioDynamics Plc to Report Fiscal Year 2020 Results on Jan 28, 2021

Oxford BioDynamics Plc Announces Retirement of Christian Hoyer Millar from Board of Directors

Oxford BioDynamics Plc to Expand Strategic Focus Beyond Biomarker Discovery to Development and Commercialization of Laboratory Tests

We're Not Very Worried About Oxford BioDynamics' (LON:OBD) Cash Burn Rate

New 90-day low: UK£0.70

Oxford BioDynamics Announces Strategic Partnership with Boca Biolistics in Order to Advance Episwitch™ Disease Severity Program for COVID-19

New 90-day high: UK£1.05

New 90-day high - UK£0.92

New 90-day high - UK£0.91

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin